Pathan Almas, Shetty Narasimha Kavitha, Naik Ankur, Ranade Arati
Jehangir Clinical Development Centre, Pune, Maharashtra, India.
IntegriMedical Private Limited, Pune, Maharashtra, India.
Med Devices (Auckl). 2024 Dec 27;17:525-536. doi: 10.2147/MDER.S491883. eCollection 2024.
The study aimed to assess the safety, tolerability, and acceptability of the IntegriMedical® Needle Free Injection System (IM-NFIS) compared to conventional hypodermic needle injections (CHN) in healthy adult subjects across multiple injection sites.
Thirty healthy male subjects aged 18-45 years were enrolled in this open-label study. Each subject received both NF and CHN injections at five different sites (forearm, abdomen, thigh, buttocks, and arm). In the study, participants in the forearm cohort received 0.1 mL of saline, whereas, for all other injection sites, 0.5 mL of saline was administered. Both needle-free and hypodermic needle injections were used at the designated sites, with a 5- to 10-minute interval between each injection. Since no active drug was used, saline served as a placebo in both methods. Safety assessments included local and systemic reactions, pain scores using the Visual Analog Scale (VAS), and acceptability questionnaires. The study adhered to ethical guidelines and was approved by the Institutional Ethics Committee.
NF injections demonstrated significantly lower pain scores compared to CHN injections (mean VAS score 0.23 vs 1.07, p < 0.01). Local site reactions were minimal and similar between NF and CHN injections, with no significant differences observed at 20-30 minutes post-injection. Systemic reactions were absent in both groups throughout the study period. The NF injection system was highly acceptable, with a majority of subjects reporting reduced anxiety and pain compared to CHN injections (p < 0.01).
IM-NFIS proved to be safe, well tolerated, and highly acceptable for delivering pharmaceuticals compared to conventional needle and syringe injections. This needle-free technology offers potential advantages in improving patient compliance and reducing injection-related anxieties, suggesting its promising role in future medical practices, including pediatric vaccinations and frequent medication administration.
本研究旨在评估IntegriMedical®无针注射系统(IM-NFIS)与传统皮下注射针(CHN)相比,在健康成年受试者多个注射部位的安全性、耐受性和可接受性。
30名年龄在18至45岁之间的健康男性受试者参与了这项开放标签研究。每个受试者在五个不同部位(前臂、腹部、大腿、臀部和手臂)接受了无针和传统皮下注射针注射。在研究中,前臂组的参与者接受了0.1 mL生理盐水注射,而在所有其他注射部位,注射了0.5 mL生理盐水。在指定部位使用了无针注射和皮下注射针注射,每次注射间隔5至10分钟。由于未使用活性药物,生理盐水在两种方法中均用作安慰剂。安全性评估包括局部和全身反应、使用视觉模拟量表(VAS)的疼痛评分以及可接受性问卷。该研究遵循伦理准则,并获得了机构伦理委员会的批准。
与传统皮下注射针注射相比,无针注射的疼痛评分显著更低(平均VAS评分为0.23对1.07,p < 0.01)。局部部位反应轻微,无针注射和传统皮下注射针注射之间相似,注射后20至30分钟未观察到显著差异。在整个研究期间,两组均未出现全身反应。无针注射系统具有高度可接受性,与传统皮下注射针注射相比,大多数受试者报告焦虑和疼痛减轻(p < 0.01)。
与传统的针头和注射器注射相比,IM-NFIS被证明在给药方面是安全、耐受性良好且高度可接受的。这种无针技术在提高患者依从性和减少注射相关焦虑方面具有潜在优势,表明其在未来医疗实践中,包括儿科疫苗接种和频繁给药方面具有广阔前景。